While the significance of these alternate forms of FGFR2 is not clear, nuclear forms of the receptor have been described previously in bone, prostate, and breast cancer suggesting a novel role for this receptor, which requires investigation [49, 50, 51]. This evidence concerns the gene FGFR2 and breast carcinoma.